Uniogen's progress toward clinical commercialization aligns with larger internal goals of bringing cancer diagnostics to market, with a specific focus on women's health.

The test helps diagnose infectious causes of vaginitis through the detection of bacteria associated with bacterial vaginosis and yeast associated with candida vaginitis.

The test could potentially deliver noninvasive results in less than one minute through analysis of exhaled volatile organic compounds.

The test, which will use Iso-PAS technology, will be developed by Nipro of Japan in collaboration with other companies, institutes, and nonprofit organizations.

The medical center will use PathAI's AISight Dx image management system to evaluate algorithms for a variety of applications.

Last week, readers were most interested in a story about FDA approving Cleveland Diagnostics' prostate cancer test.

NEW YORK – Cancer detection company Freenome said Friday that it plans to go public on the Nasdaq through a merger with publicly traded special purpose acquisition company Perceptive Capital Solutions ...

The test, which will use Iso-PAS technology, will be developed by Nipro of Japan in collaboration with other companies, institutes, and nonprofit organizations. UMC Utrecht, PathAI Partner on Digital ...

Hims & Hers obtains YourBio's microsampling tech, which the firm said will speed its efforts to improve blood collection, including outside traditional clinical settings.

The funding will support a collaboration between ProtonDx and Imperial College London to evaluate a host gene expression test on a next-gen test system.

The company is developing a noninvasive urine-based test for sexually transmitted infections including chlamydia and gonorrhea.